Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center

Inclusion Criteria: * HIV-1 infection, documented in medical record at any time prior to study entry. * Men and women age18 years to 80 years. * Presence of COPD (FEV1/FVC\<0.70 or DLco≤80% predicted) * No lipid-lowering medication (prescription or non-prescription) within 60 days prior to study entry. This includes all statin drugs, omega-3-fatty acids/fish oil (if dose \> 1 g/day), red yeast rice (any dose), and niacin products (e.g., niacin, nicotinic acid, vitamin B3; if dose of \>100 mg/day) * Normal liver and kidney function test at screening visit: * Liver function: ALT 7 to 55 U/L; AST 8 to 48 U/L; ALP 45 to 115 U/L; Bilirubin 0.1 to 1.0 mg/dL; GGT 9 to 48 U/L; LDH 122 to 222 umol/L; PT 8.3 to 10.8 seconds * Kidney function: BUN 8-20 mg/dl. Creatinine 0.8-1.2 mg/dl for males and 0.6-0.9 mg/dl for females. GFR normal results range from 90 - 120 mL/min/1.73 m2.) Participants will be on a stable ART regimen (i.e. no change in agents) with either suppressed HIV viral level or \<50 viral level for at least 3 months. * If smoker, not planning on quitting smoking during the study period. If non-smoker, not planning on starting smoking during the study period. * Able to provide informed consent. * Able to participate in study procedures based on the investigator's assessment. * For women of reproductive potential, negative urine pregnancy test and willingness to use birth control during study period (see Contraception requirements). * Ability and willingness to complete all tests. * Participant in MACS, Women's Interagency Health Study, or Attendee of UPMC HIV / AIDS Program. Exclusion Criteria: * Pregnancy or breast-feeding. * Known allergy/sensitivity or any hypersensitivity to HMG CoA reductase inhibitors, prior history of myopathy, rhabdomyolysis, or intolerance of statin therapy. * Currently receiving a statin or should be taking a statin based on clinical criteria. * Concurrent use of Coumadin. * History of liver disease. * Contraindication to pulmonary function testing (i.e. abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.). * Diagnosis of asthma with normal diffusing capacity. * History of diabetes mellitus requiring medication of hemoglobin A1C\>6.5% on screening laboratories. * Increasing respiratory symptoms or febrile (temperature \>100.40F \[380C\]) within 4 weeks of study entry. * Hospitalization within 4 weeks prior to study entry. * Use of antibiotics within 4 weeks of study entry. * Uncontrolled hypertension at screening visit (systolic \> 160 mm Hg or diastolic \> 100 mm Hg) from an average of two or more readings. Subject may return for screening after blood pressure is controlled. * Active cancer requiring systemic chemotherapy or radiation. * Active infection of lungs, brain, or abdomen. * Use of anti-inflammatory agents (such as aspirin), immunomodulators (e.g., interleukins, interferons, cyclosporine) or immunosuppressive medications within 60 days prior to study entry. Routine vaccinations are allowed if administered at least 7 days prior to study entry. * Use of azole antifungals, erythromycin, or amiodarone. * More than weekly use of magnesium hydroxide. * The intention to quit smoking during the study period. * Alcoholism defined as \>35 drinks per week or that will impair ability to complete study investigations in the opinion of the investigator. * Active (within the past 6 months) intravenous drug use or that will impair ability to complete study investigations in the opinion of the investigator. * Use of other investigational agents within 90 days of study entry or planning on entering another therapy trial during study period. * No use of inhaled corticosteroids (beta-agonists are allowed). * Viral load above 50 in past 3 months.